


AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1-14. (Cancelled)

15. (Currently Amended) A compound of the formula (I):



wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkyl-cycloalkyl-, heteroaryl- or heteroarylalkyl group,

U is hydrogen, a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroaryl-alkyl group,

G-E is selected from the following groups,



O



or is part of an optionally substituted phenyl ring,

V-W is a group of the formula CH-CH or C=C (cis or trans),

R¹ is a C₁-C₄ alkyl- or a C₃-C₄-cycloalkyl group,

X is oxygen ~~or a group of the formula NR², wherein R² is hydrogen, a alkyl-, alkenyl-, alkynyl-, hetero-alkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcyclo-alkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl group,~~

Y is oxygen ~~or a group of the formula NR¹⁰, wherein R¹⁰ is hydrogen, oxygen, a OH, NH₂, alkyl- or a heteroalkyl group (as for example a alkyl-oxo-, alkyl-amino- or dialkylamino-group),~~


R³ and R⁴ are independently of each other hydrogen, a C₁-C₄ alkyl group or together are part of a cycloalkyl group with 3 or 4 ring atoms, and

R⁹ is hydrogen, a alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkyl-cycloalkyl-, heteroalkylcycloalkyl-, heterocyclo-alkyl-, aralkyl- or a heteroaralkyl group,


or a pharmacologically acceptable salt, ~~solvate, hydrate or a pharmacologically acceptable formulation thereof.~~

16. (Previously Presented) A compound of claim 15 wherein A is a group of the formula -C(CH₃)=CHR⁵ or -CH=CHR⁵, wherein R⁵ is a heteroaryl- or a heteroarylalkyl group.

17. (Currently Amended) A compound of claim 15 wherein A is a group of the formula (II) or (III):



(II)



(III)

wherein

Q a sulphur, oxygen or a group of the formula NR⁷ wherein R⁷ is hydrogen, a C₁-C₄ alkyl group or a C₁-C₄-heteroalkyl group, z is nitrogen or a CH group and R⁶ is a group of the formula OR⁸ or NHR⁸, a alkyl-, alkenyl, ~~alkynyl-~~ alkynyl- or a heteroalkyl group, wherein R⁸ is hydrogen, a C₁-C₄-alkyl group or a C₁-C₄-heteroalkyl group.

18. (Previously Presented) A compound of claim 17 wherein z is a CH-group.
19. (Previously Presented) A compound of claim 17 wherein Q is sulphur or oxygen.
20. (Previously Presented) A compound of claim 17 wherein R⁶ is a group of the formula CH₃, CH₂OH or CH₂NH₂.
21. (Canceled)
22. (Previously Presented) A compound of claim 15 wherein R¹ is a methyl group.
23. (Previously Presented) A compound of claim 15 wherein R³ and R⁴ are methyl groups.
24. (Previously Presented) A compound of claim 15 wherein U is hydrogen.
25. (Previously Presented) A compound of claim 15 wherein R⁹ is hydrogen.
26. (Canceled)
27. (Previously Presented) A pharmaceutical composition comprising a compound of claim 15.
28. (Previously Presented) The pharmaceutical composition of claim 27 further comprising one or more carriers and/or adjuvants.
29. (Withdrawn – Currently Amended) A method for treating a patient suffering from or susceptible to cancer comprising administering to the patient an effective amount of the compound of claim 15.
30. (Withdrawn) The method of claim 29 wherein the patient is suffering from cancer.
31. (Withdrawn – Currently Amended) The method of claim 29 wherein the patient has been identified as suffering from cancer and selected for treatment for cancer and the compound is administered to the identified and selected patient.